Filter by: patients
What is Avodart?

AVODART is a brand name for dutasteride which is used to treat symptomatic benign prostatic hyperplasia (BPH) and to reduce the risk of acute urinary retention (AUR) and prostate surgery.

Reported Purpose & Efficacy

Reasons and Efficacy
Purpose # of patients
# of patients with evaluations Efficacy
Major
Moderate
Slight
None
Can’t tell
Other 7 1 Efficacy_moderate
Swollen prostate 3 1 Efficacy_none
enlarged prostrate 3 0
General health 2 0
Prostate Cancer 2 0
Frequent night time urination 1 0

See all 16 patients currently taking Avodart

Mouse over the table for more information

Reported Side Effects

Side effects as an overall problem

Severe
0
Moderate
1
Mild
1
None
0

Commonly reported side effects, conditions, and hospitalizations associated with Avodart

Semen production decreased 1

Reported Dosages

  0.5mg as needed daily 0.5 mg every other week 0.5 mg daily
  1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1 13 Number of Patients: 13  

Reported Stop Reasons

Why Patients Stopped Taking Avodart (multiple reasons could be selected)
Reason # Patients Percentage of patients
Did not seem to work 1   Did not seem to work: 50%
Side effects too severe 1   Side effects too severe: 50%

See all 2 patients who’ve stopped taking Avodart

Currently Taking Avodart

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0

Stopped Taking Avodart

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0

Reported Adherence, Burden & Cost See details from patient evaluations

Adherence

Taking treatment as prescribed

Adherence of Avodart

Always
2 100%
Usually
0 0%
Sometimes
0 0%
Never
0 0%

Burden

Difficulty being on treatment

Burden of Avodart

Very
0 0%
Somewhat
0 0%
A little
1 50%
Not at all
1 50%

Cost

Paid out of pocket

Cost of Avodart

$200+
0 0%
$100-199
0 0%
$50-99
0 0%
$25-49
0 0%
< $25
1 100%

See more information, including instructions, precautions, side effects, and interactions.

Report created on May 26, 2012.